Alkermes announced on May 12 that Lumryz, its once-nightly sodium oxybate gained in the $2.37 billion Avadel acquisition, hit all primary and key secondary endpoints in the phase 3 Revitalyz trial for idiopathic hypersomnia. The placebo-controlled study showed statistically significant improvement in daytime sleepiness on the Epworth Sleepiness Scale, with a p‑value under 0.0001. Meanwhile, patients on placebo reported worsening symptoms on both PGI‑C and IHSS measures, also below that threshold. Alkermes intends to seek FDA approval by late 2026, which would trigger a $1.50 per‑share contingent value right for Avadel holders if Lumryz wins approval by 2028. The data drop comes about three months after the Avadel deal closed and extends the drug’s reach beyond its 2023 narcolepsy approval.
This strong phase 3 result gives Alkermes quick validation of the acquisition and positions it squarely against Jazz Pharmaceuticals’ Xywav, the current market leader in idiopathic hypersomnia. The once‑nightly profile should resonate in what CCO Todd Nichols has called an “underdeveloped category” of roughly 40,000 diagnosed patients. If Lumryz earns the new label by 2028, it would open a second major indication and chip away at Jazz’s growth engine. It also reflects Alkermes’ larger push to scale in rare neurology rather than lean too heavily on psychiatry and oncology. The company finally looks like it knows what it wants to be when it grows up.
Investors are already asking whether the company will move its filing up to mid‑2026 to gain earlier visibility and activate the contingent payout sooner. Payers are bracing for tougher formulary negotiations as both products converge on the same treatment population. Expect Jazz to defend its territory through contracting while Alkermes tests its still‑new commercial muscle in sleep medicine. For pricing and coverage patterns across sodium oxybate brands, see RxInfo.ai.
